Fadi G Haddad
Overview
Explore the profile of Fadi G Haddad including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
54
Citations
269
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kugler E, Kantarjian H, Jabbour E, Khaire N, Short N, Kadia T, et al.
Cancer
. 2025 Feb;
131(5):e35773.
PMID: 39980368
Background: The BCR::ABL1 tyrosine kinase inhibitors (TKIs) have significantly improved the outcomes of patients with Philadelphia chromosome (Ph)-positive acute lymphoblastic leukemia (ALL). However, the optimal duration of TKI therapy in...
2.
Shen Q, Tang G, Haddad F, Chen W, Wang W, Wang W, et al.
Leuk Lymphoma
. 2025 Jan;
1-4.
PMID: 39801075
No abstract available.
3.
Senapati J, Kantarjian H, Habib D, Haddad F, Jain N, Short N, et al.
Leuk Lymphoma
. 2025 Jan;
1-12.
PMID: 39791458
Using immunotherapeutic agents like inotuzumab ozogamicin (InO), blinatumomab, or chimeric antigen receptor T (CAR T)-cell therapy in frontline adult B-cell acute lymphoblastic leukemia (B-ALL) therapy is promising. These agents are...
4.
Kantarjian H, Short N, Jain N, Haddad F, Kadia T, Yilmaz M, et al.
Am J Hematol
. 2025 Jan;
100(3):402-407.
PMID: 39757533
Adding inotuzumab ozogamicin (InO) to hyper-CVAD and blinatumomab may improve outcomes in newly diagnosed Philadelphia chromosome (Ph)-negative B-cell acute lymphoblastic leukemia (B-ALL). Patients with newly diagnosed B-ALL received up to...
5.
Senapati J, Kantarjian H, Haddad F, Short N, Borthakur G, Kanagal-Shamanna R, et al.
Am J Hematol
. 2024 Dec;
100(2):249-259.
PMID: 39718824
Patients who develop acute myeloid leukemia (AML) after having received treatment for myelodysplastic syndrome (MDS) or related conditions have particularly poor outcomes. This study analyzed adult patients with newly diagnosed...
6.
Senapati J, Loghavi S, Garcia-Manero G, Tang G, Kadia T, Short N, et al.
Haematologica
. 2024 Dec;
PMID: 39665206
In myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) with TP53 aberrations, dissecting the interaction amongst patient, disease and treatment factors are important for therapeutic decisions and prognostication. This retrospective...
7.
Haddad F, Sasaki K, Senapati J, Hu S, Dellasala S, Issa G, et al.
Clin Lymphoma Myeloma Leuk
. 2024 Nov;
PMID: 39592322
Introduction: The discontinuation of third-generation BCR::ABL1 tyrosine kinase inhibitors (TKIs) in patients with chronic myeloid leukemia in chronic phase (CML-CP) is not well understood. We aim to evaluate treatment-free remission...
8.
Short N, Nguyen D, Jabbour E, Senapati J, Zeng Z, Issa G, et al.
Lancet Haematol
. 2024 Sep;
11(11):e839-e849.
PMID: 39303729
Background: Advanced phase Philadelphia chromosome-positive myeloid disease-consisting of chronic myeloid leukaemia in the myeloid blast phase and in the accelerated phase, and Philadelphia chromosome-positive acute myeloid leukaemia-is associated with poor...
9.
Jen W, Jabbour E, Short N, Issa G, Haddad F, Jain N, et al.
Am J Hematol
. 2024 Aug;
99(11):2229-2232.
PMID: 39194286
Twenty adults with newly diagnosed (ND) or relapsed/refractory (RR) Ph-positive acute lymphoblastic leukemia (ALL), or chronic myeloid leukemia in lymphoid blast phase (CML-LBP), were treated with mini-hyperCVD, ponatinib, and blinatumomab....
10.
Cuglievan B, Kantarjian H, Rubnitz J, Cooper T, Zwaan C, Pollard J, et al.
Leukemia
. 2024 Aug;
38(10):2073-2084.
PMID: 39179671
Aberrant expression of HOX and MEIS1 family genes, as seen in KMT2A-rearranged, NUP98-rearranged, or NPM1-mutated leukemias leads to arrested differentiation and leukemia development. HOX family genes are essential gatekeepers of...